ABVC BioPharma

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

ABVC BioPharma Inc

Press Releases

ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones

Health Care

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

General

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

ABVC

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Aligos Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

BeyondSpring

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Cibus

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CervoMed

Fortress Biotech

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Immunic

MiNK Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

IO Biotech

Jasper Therapeutics, Inc. - Class A Common Stock

Comments

ABVC BioPharma

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO